Division of Basic Neurosciences, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Department of Neurology, Columbia University, New York, New York, USA.
Mov Disord. 2020 Nov;35(11):2095-2100. doi: 10.1002/mds.28175. Epub 2020 Jul 11.
Leucine-rich repeat kinase 2 kinase inhibitors are being vigorously pursued as potential therapeutic options; however, there is a critical need for sensitive and quantitative assays of leucine-rich repeat kinase 2 function and target engagement.
Our objective was to compare collection and storage protocols for peripheral blood mononuclear cells, and to determine the optimal conditions for downstream analyses of leucine-rich repeat kinase 2 in PD cohorts.
Here, we describe enzyme-linked immunosorbent assay-based assays capable of detecting multiple aspects of leucine-rich repeat kinase 2 function at endogenous levels in human tissues.
In peripheral blood mononuclear cells from both healthy and affected carriers of the G2019S mutation in leucine-rich repeat kinase 2, we report, for the first time, significantly elevated in vitro kinase activity, while detecting a significant increase in pS935/leucine-rich repeat kinase 2 in idiopathic PD patients.
Quantitative assays such as these described here could potentially uncover specific markers of leucine-rich repeat kinase 2 function that are predictive of disease progression, aid in patient stratification, and be a critical component of upcoming clinical trials. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
富含亮氨酸重复激酶 2 激酶抑制剂作为潜在的治疗选择正在被大力研究;然而,迫切需要灵敏且定量的检测富含亮氨酸重复激酶 2 功能和靶标结合的方法。
我们的目的是比较外周血单核细胞的采集和储存方案,并确定用于 PD 队列中富含亮氨酸重复激酶 2 的下游分析的最佳条件。
在这里,我们描述了基于酶联免疫吸附测定的检测方法,这些方法能够在人类组织中以内源性水平检测富含亮氨酸重复激酶 2 功能的多个方面。
我们首次报道,在富含亮氨酸重复激酶 2 的 G2019S 突变的健康和受影响携带者的外周血单核细胞中,体外激酶活性显著升高,而在特发性 PD 患者中检测到 pS935/富含亮氨酸重复激酶 2 的显著增加。
如这里所述的定量检测方法可能会揭示富含亮氨酸重复激酶 2 功能的特定标志物,这些标志物可预测疾病进展,有助于患者分层,并成为即将到来的临床试验的关键组成部分。© 2020 作者。运动障碍协会由 Wiley 期刊出版公司代表国际帕金森病和运动障碍协会出版。